ArticleOpen forum infectious diseases2019
Effect of a Single Standard Dose (150-200 μg/kg) of Ivermectin on
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review.Parasites & vectors · 2025Pooled it
- Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial.PLoS neglected tropical diseases · 2025Trial
- Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin inOpen forum infectious diseases · 2024Trial
- The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Trial
- Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.PLoS neglected tropical diseases · 2025Article
- Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru.Parasite epidemiology and control · 2023Review
- Broadening the range of use cases for ivermectin - a review of the evidence.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Review
- Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators ofPathogens (Basel, Switzerland) · 2020Article
- Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children.PLoS neglected tropical diseases · 2020Article
- Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.The Lancet. Infectious diseases · 2020Observational
- Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations.Open forum infectious diseases · 2019Article
- Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy.Emerging infectious diseases · 2019Article
- Current therapeutic applications and pharmacokinetic modulations of ivermectin.Veterinary world · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn central Africa, millions of individuals infected with
methodsWe conducted a systematic review of trials on the effect of a single standard (150-200 μg/kg) dose of IVM on
resultsIVM brings about a rapid, dramatic, and sustained decrease, with reduction rates of 60%, 75%, 85%, and 90% on day 1 (D1), D2, D7, and D365, respectively. At D365, no participants (0/238) with an initial MFD of <20 000 microfilariae (mf)/mL were at risk of postivermectin severe adverse events, and only 1/57 individuals with an initial MFD of ≥20 000 mf/mL presented with an MFD above this value. The main predictor of post-treatment MFD was the pretreatment value, but this post-treatment value varied little between D8 and D365 regardless of the pretreatment level.
conclusionsA single dose of IVM is very effective at substantially reducing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.